142 related articles for article (PubMed ID: 10859012)
1. High intratumoral accumulation of stealth liposomal doxorubicin in sarcomas--rationale for combination with radiotherapy.
Koukourakis MI; Koukouraki S; Giatromanolaki A; Kakolyris S; Georgoulias V; Velidaki A; Archimandritis S; Karkavitsas NN
Acta Oncol; 2000; 39(2):207-11. PubMed ID: 10859012
[TBL] [Abstract][Full Text] [Related]
2. Liposomal doxorubicin and conventionally fractionated radiotherapy in the treatment of locally advanced non-small-cell lung cancer and head and neck cancer.
Koukourakis MI; Koukouraki S; Giatromanolaki A; Archimandritis SC; Skarlatos J; Beroukas K; Bizakis JG; Retalis G; Karkavitsas N; Helidonis ES
J Clin Oncol; 1999 Nov; 17(11):3512-21. PubMed ID: 10550149
[TBL] [Abstract][Full Text] [Related]
3. High intratumoural accumulation of stealth liposomal doxorubicin (Caelyx) in glioblastomas and in metastatic brain tumours.
Koukourakis MI; Koukouraki S; Fezoulidis I; Kelekis N; Kyrias G; Archimandritis S; Karkavitsas N
Br J Cancer; 2000 Nov; 83(10):1281-6. PubMed ID: 11044350
[TBL] [Abstract][Full Text] [Related]
4. Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group.
Judson I; Radford JA; Harris M; Blay JY; van Hoesel Q; le Cesne A; van Oosterom AT; Clemons MJ; Kamby C; Hermans C; Whittaker J; Donato di Paola E; Verweij J; Nielsen S
Eur J Cancer; 2001 May; 37(7):870-7. PubMed ID: 11313175
[TBL] [Abstract][Full Text] [Related]
5. Liposomal doxorubicin (Caelyx) in advanced pretreated soft tissue sarcomas: a phase II study of the Italian Sarcoma Group (ISG).
Toma S; Tucci A; Villani G; Carteni G; Spadini N; Palumbo R
Anticancer Res; 2000; 20(1B):485-91. PubMed ID: 10769710
[TBL] [Abstract][Full Text] [Related]
6. Radiation improves the distribution and uptake of liposomal doxorubicin (caelyx) in human osteosarcoma xenografts.
Davies Cde L; Lundstrøm LM; Frengen J; Eikenes L; Bruland S ØS; Kaalhus O; Hjelstuen MH; Brekken C
Cancer Res; 2004 Jan; 64(2):547-53. PubMed ID: 14744768
[TBL] [Abstract][Full Text] [Related]
7. Selective delivery of doxorubicin to patients with breast carcinoma metastases by stealth liposomes.
Symon Z; Peyser A; Tzemach D; Lyass O; Sucher E; Shezen E; Gabizon A
Cancer; 1999 Jul; 86(1):72-8. PubMed ID: 10391566
[TBL] [Abstract][Full Text] [Related]
8. Phase I trial of preoperative doxorubicin-based concurrent chemoradiation and surgical resection for localized extremity and body wall soft tissue sarcomas.
Pisters PW; Patel SR; Prieto VG; Thall PF; Lewis VO; Feig BW; Hunt KK; Yasko AW; Lin PP; Jacobson MG; Burgess MA; Pollock RE; Zagars GK; Benjamin RS; Ballo MT
J Clin Oncol; 2004 Aug; 22(16):3375-80. PubMed ID: 15310783
[TBL] [Abstract][Full Text] [Related]
9. Phase 1 European Organisation for Research and Treatment of Cancer study determining safety of pegylated liposomal doxorubicin (Caelyx) in combination with ifosfamide in previously untreated adult patients with advanced or metastatic soft tissue sarcomas.
Nielsen OS; Reichardt P; Christensen TB; Pink D; Daugaard S; Hermans C; Marreaud S; van Glabbeke M; Blay J; Judson I
Eur J Cancer; 2006 Sep; 42(14):2303-9. PubMed ID: 16891112
[TBL] [Abstract][Full Text] [Related]
10. Low-dose tumor necrosis factor-alpha augments antitumor activity of stealth liposomal doxorubicin (DOXIL) in soft tissue sarcoma-bearing rats.
Ten Hagen TL; Van Der Veen AH; Nooijen PT; Van Tiel ST; Seynhaeve AL; Eggermont AM
Int J Cancer; 2000 Sep; 87(6):829-37. PubMed ID: 10956394
[TBL] [Abstract][Full Text] [Related]
11. Phase I study of paclitaxel (taxol) and pegylated liposomal doxorubicin (caelyx) administered every 2 weeks in patients with advanced solid tumors.
Mavroudis D; Kouroussis Ch; Kakolyris S; Agelaki S; Kalbakis K; Androulakis N; Souglakos J; Samonis G; Georgoulias V
Oncology; 2002; 62(3):216-22. PubMed ID: 12065868
[TBL] [Abstract][Full Text] [Related]
12. Long-term pharmacokinetics of doxorubicin HCl stealth liposomes in patients after polychemotherapy with vinorelbine, cyclophosphamide and prednisone (CCVP).
Linkesch W; Weger M; Eder I; Auner HW; Pernegg C; Kraule C; Czejka MJ
Eur J Drug Metab Pharmacokinet; 2001; 26(3):179-84. PubMed ID: 11695718
[TBL] [Abstract][Full Text] [Related]
13. A dose-finding study of temsirolimus and liposomal doxorubicin for patients with recurrent and refractory bone and soft tissue sarcoma.
Thornton KA; Chen AR; Trucco MM; Shah P; Wilky BA; Gul N; Carrera-Haro MA; Ferreira MF; Shafique U; Powell JD; Meyer CF; Loeb DM
Int J Cancer; 2013 Aug; 133(4):997-1005. PubMed ID: 23382028
[TBL] [Abstract][Full Text] [Related]
14. Phase II trial of pegylated-liposomal doxorubicin (Doxil) in sarcoma.
Skubitz KM
Cancer Invest; 2003 Apr; 21(2):167-76. PubMed ID: 12743981
[TBL] [Abstract][Full Text] [Related]
15. Liposomal doxorubicin in conjunction with reirradiation and local hyperthermia treatment in recurrent breast cancer: a phase I/II trial.
Kouloulias VE; Dardoufas CE; Kouvaris JR; Gennatas CS; Polyzos AK; Gogas HJ; Sandilos PH; Uzunoglu NK; Malas EG; Vlahos LJ
Clin Cancer Res; 2002 Feb; 8(2):374-82. PubMed ID: 11839652
[TBL] [Abstract][Full Text] [Related]
16. (99m)Tc-labelled Stealth liposomal doxorubicin (Caelyx) in glioblastomas and metastatic brain tumours.
Laverman P; Boerman OC; Storm G; Oyen WJ
Br J Cancer; 2002 Feb; 86(4):659-61. PubMed ID: 11870553
[No Abstract] [Full Text] [Related]
17. Pegylated liposomal tumor necrosis factor-alpha results in reduced toxicity and synergistic antitumor activity after systemic administration in combination with liposomal doxorubicin (Doxil) in soft tissue sarcoma-bearing rats.
ten Hagen TL; Seynhaeve AL; van Tiel ST; Ruiter DJ; Eggermont AM
Int J Cancer; 2002 Jan; 97(1):115-20. PubMed ID: 11774252
[TBL] [Abstract][Full Text] [Related]
18. Doxil (Caelyx): an exploratory study with pharmacokinetics in patients with hormone-refractory prostate cancer.
Hubert A; Lyass O; Pode D; Gabizon A
Anticancer Drugs; 2000 Feb; 11(2):123-7. PubMed ID: 10789595
[TBL] [Abstract][Full Text] [Related]
19. Phase I and pharmacokinetic study of a stable, polyethylene-glycolated liposomal doxorubicin in patients with solid tumors: the relation between pharmacokinetic property and toxicity.
Hong RL; Tseng YL
Cancer; 2001 May; 91(9):1826-33. PubMed ID: 11335910
[TBL] [Abstract][Full Text] [Related]
20. Caelyx (stealth liposomal doxorubicin) in the treatment of advanced breast cancer.
Ranson MR; Cheeseman S; White S; Margison J
Crit Rev Oncol Hematol; 2001 Feb; 37(2):115-20. PubMed ID: 11166584
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
